TriSalus Life Sciences Competitors and Similar CompaniesClear all
TriSalus Life Sciences's competitors and similar companies include RenovoRx, ChemoCentryx, Turning Point Therapeutics and NATCO Pharma.
 TriSalus Life Sciences TriSalus Life Sciences (formerly MedTech Acquisition and Surefire Medical) is a company that develops a transformative platform for treating liver and pancreatic tumors. |  RenovoRx RenovoRx is a clinical-stage biopharmaceutical company focused on developing therapies for the local treatment of solid tumors. |  ChemoCentryx ChemoCentryx is a biopharmaceutical company commercializing and developing medications for inflammatory and autoimmune diseases and cancer. |  Turning Point Therapeutics Turning Point Therapeutics (TP Therapeutics) is a precision oncology company that is engaged in medicine discovery for cancer and other diseases. |  NATCO Pharma NATCO Pharma is a company focused on research, manufacturing, and marketing of finished dosage formulations (FDF) and active pharmaceutical ingredients (API). | |
Founding Date | Founding Date 2009 | Founding Date 2012 | Founding Date 1997 | Founding Date 2013 | Founding Date 1981 |
Type | Type Public | Type Public | Type Subsidiary | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Westminster, US HQ Bannockburn, US Cranston, US | Locations Los Altos, US HQ | Locations San Carlos, US HQ | Locations San Diego, US HQ | Locations Hyderabad, IN HQ Central Hope Town, IN Chennai, IN Hyderabad, IN Santola, IN Vijayapuri North, IN |
Employees | Employees 106 | Employees 7 | Employees 51 | Employees 474% decrease | Employees 4,016 |
Valuation ($) | Valuation ($) 117.2 m | Valuation ($) 24.8 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $45.2m (FY, 2025) | Revenue (est.) $1.1m (FY, 2025) | Revenue (est.) $32.2m (FY, 2021) | Revenue (est.) $30.8m (FY, 2021) | Revenue (est.) ₹44.1b (FY, 2025) |
Cost of goods | Cost of goods $7m (FY, 2025) | Cost of goods $327k (FY, 2025) | Cost of goods $302k (FY, 2021) | Cost of goods N/A | Cost of goods ₹7.5b (FY, 2025) |
Gross profit | Gross profit $38.2m (FY, 2025) | Gross profit $796k (FY, 2025) | Gross profit $31.9m (FY, 2021) | Gross profit N/A | Gross profit ₹37b (FY, 2025) |
Net income | Net income ($39.2m) (FY, 2025) | Net income ($11.2m) (FY, 2025) | Net income ($131.8m) (FY, 2021) | Net income ($236.6m) (FY, 2021) | Net income ₹18.8b (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 52.2m | Total funding raised $ 10.2m | Total funding raised $ 149.5m | Total funding raised $ 144.4m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
RenovoRx
HQ
Los Altos, US
Employees
7
RenovoRx is a clinical-stage biopharmaceutical company focused on developing therapies for the local treatment of solid tumors.
View companyChemoCentryx
HQ
San Carlos, US
ChemoCentryx is a biopharmaceutical company commercializing and developing medications for inflammatory and autoimmune diseases and cancer.
View companyTurning Point Therapeutics
HQ
San Diego, US
Turning Point Therapeutics (TP Therapeutics) is a precision oncology company that is engaged in medicine discovery for cancer and other diseases.
View companyNATCO Pharma
HQ
Hyderabad, IN
Employees
4,016
NATCO Pharma is a company focused on research, manufacturing, and marketing of finished dosage formulations (FDF) and active pharmaceutical ingredients (API).
View company